CellRapeutics™ In Vivo CAR-NK Cell Engineering Service

Are you navigating the challenges of exorbitant manufacturing expenses, intricate supply chain logistics, and the mandatory yet toxic lymphodepletion regimen in your cell therapy program? Creative Biolabs' CellRapeutics™ In Vivo CAR-NK Cell Engineering Service platform offers a transformative alternative. We directly administer genetic payloads systemically to generate functional CAR-NK cells within the patient's own immune system, utilizing advanced targeted delivery technologies, which fundamentally bypasses costly ex vivo expansion and eliminates preconditioning chemotherapy. We develop a truly scalable, readily available therapeutic modality.

Introduction

CAR-NK cell therapy is an innovative immunotherapeutic strategy that involves genetically engineering NK cells to express a CAR targeting specific tumor antigens, thereby enabling them to selectively recognize and eliminate malignant cells. Compared to CAR-T cell therapy, CAR-NK cells offer distinct advantages, including broader cell source availability, no requirement for strict human leukocyte antigen (HLA) matching, feasibility as an "off-the-shelf" therapeutic product, and a lower risk of severe cytokine release syndrome (CRS) or graft-versus-host disease (GVHD). These attributes underscore their favorable safety profile and considerable therapeutic potential in the treatment of both hematological malignancies and solid tumors.

Fig.1 Design and optimization of CAR constructs in CAR-NK cell therapy.¹

CellRapeutics™ In Vivo CAR-NK Cell Engineering Service at Creative Biolabs

Creative Biolabs' CellRapeutics™ In Vivo CAR-NK Cell Engineering Service leverages cell specific delivery of non-viral or engineered viral vectors, bypassing the requirement for preconditioning chemotherapy and resource-intensive ex vivo production. Our platform enables the concurrent induction of multiple cytotoxic immune subsets, extends functional durability via integrated cytokine signaling, and provides a highly efficacious, safer, and operationally simplified therapeutic modality.

What We Can Offer

We offer a comprehensive suite of technologies for In vivo CAR-NK Development, including targeted cellular engraftment via engineered chemokine receptors, CAR expression control with tissue-specific promoters, enhanced persistence through cytokine co-expression, and immune checkpoint blockade to overcome the suppressive tumor microenvironment.

Our in vivo engineering portfolio extends immune cell reprogramming beyond T cells.

• In vivo B Cell Engineering Service

We reprogram B cells in vivo to secrete therapeutic proteins, enabling targeted protein replacement and immunomodulation with sustained, site-specific expression.

• In vivo CAR-M Cell Engineering Service

We generate CAR macrophages directly in vivo to enhance tumor phagocytosis, remodel the TME, and drive durable anti-tumor immunity with a favorable safety profile.

Our Service Process

Required starting materials:

• Target Antigen Sequences: Optimized Single-Chain Variable Fragment (scFv) sequences specific to the target antigen.
• Specific Cell-Type Promoters: Regulatory elements to ensure the CAR transgene is expressed only in the desired immune cell populations.
• Reporter Gene Constructs (optional): Luciferase or fluorescent reporter gene sequences essential for non-invasive in vivo tracking and quantification of therapeutic cell distribution and expansion.

Key Steps:

Final Deliverables:

• Finalized Gene Delivery Vector (LNP or Viral): High-titer, quality-controlled vector suitable for large-scale production.
• Efficacy Data Package: Comprehensive report including in vivo CAR expression, therapeutic cell persistence, TME analysis, and tumor growth curves.
• Safety & Off-Target Verification Report: Detailed analysis of genomic integrity, off-target editing, and cell specific targeting selectivity.

Key Advantages

• Tailored CAR Architecture and Functional Enhancement: Our team specializes in the bespoke design and optimization of CAR constructs, including signaling domains and cytokine armoring, to enhance in vivo durability, functional persistence, and tumoricidal efficacy for your selected immune cell type and target antigen.
• Adaptive and Optimized Delivery Solutions: We offer a flexible delivery strategy, customizing the platform choice, from non-viral lipid nanoparticles to engineered viral vectors, based on your project's cellular targeting needs, dosing schedule, and long-term safety profile, supported by scalable batch, fed-batch, or continuous production processes.
• Integrated Large-Scale Vector Production: We provide end-to-end manufacturing of clinical-grade gene delivery vectors (LNP or viral), with scalable capacity from pilot studies to commercial-scale volumes, ensuring reliable supply and seamless transition through clinical development.

FAQ

Why Choose Us?

We pioneer safe and potent in vivo CAR-NK solutions. Our core non-viral mRNA-LNP platform eliminates the risks of genomic integration and avoids lymphodepletion, while leveraging NK cells' dual natural and ADCP-mediated cytotoxicity. This is validated by rigorous off-target profiling to ensure clinical-grade safety and efficacy from concept to clinic.

Customer Reviews

"By integrating Creative Biolabs' In vivo CAR-NK Development platform into our study, we achieved a marked enhancement in therapeutic cell longevity in vivo, primarily through their advanced IL-15 armoring strategy. The resulting functional persistence proved to be twice as durable compared to conventional CAR designs."— Dr. L***a S.

"We selected Creative Biolabs based on their emphasis on preserving the innate cytotoxicity of NK cells beyond CAR-directed targeting, a key advantage for addressing highly heterogeneous tumors. Their comprehensive tumor microenvironment assessment, provided as part of the service, played a pivotal role in shaping our combined treatment approach."— Prof. J***n H.

"The rigorous off-target profiling integrated into Creative Biolabs' In vivo CAR-NK Development process represented a decisive benefit for our program. It directly alleviated our safety concerns related to genomic integration and delivered the precise dataset required to advance our pre-IND submission without delay."— M***a K.

How to Contact Us?

Unlock your therapeutic potential by partnering with Creative Biolabs. We specialize in pioneering in vivo CAR-NK engineering and next-generation delivery platforms to accelerate your candidate's transition into clinical development.

Connect with our experts to explore customized strategies for your program.

Reference

1. Li, Wangshu et al. "CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges." Biomolecules vol. 14,8 1035. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/biom14081035. 20 Aug. 2024, doi:10.3390/biom14081035